Skystar Bio-Pharmaceutical Company (SKBI) 3.79 $SKBI
InsiderInsights.com Daily Round Up 4/20/15: AXDX, BXMT, OPK, AGCO
InsiderInsights - at Seeking Alpha - Wed Apr 22, 10:38AM CDT
STFC: 23.83 (-0.01), SKBI: 3.79 (-0.11), DOOR: 68.54 (-0.82), MMI: 37.17 (-0.02), AGCO: 48.16 (-0.16), DEI: 29.37 (+0.22), ABDC: 13.70 (-0.19), CSX: 36.26 (+0.91), HOV: 3.36 (-0.08), MOH: 63.02 (-0.71), MEMP: 16.95 (-0.16), SFS: 18.08 (-0.49), AXDX: 23.62 (+0.10), OPK: 14.60 (+0.17), BXMT: 31.24 (+0.04), FELP: 13.99 (-0.33), CRM: 67.71 (+0.33)
Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K
Marketwired - Wed Apr 15, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market ("Nasdaq"
informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol.
SKBI: 3.79 (-0.11)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 133.71 (+0.57), SKBI: 3.79 (-0.11), PTBI: 3.37 (+0.20), FMD: 6.56 (+0.01), GHC: 1,068.93 (+24.92), VRML: 1.80 (-0.02), ADBE: 75.50 (+0.88), OHAI: 5.59 (+0.03), KERX: 11.52 (-0.15), BH: 396.99 (-5.47), LII: 107.70 (+2.09), JAZZ: 186.13 (-0.41), NMBL: 24.61 (-0.13), REGN: 472.63 (+9.41), OAS: 16.47 (-0.36), XLRN: 33.67 (-0.02), SYK: 96.45 (+1.74), CRM: 67.71 (+0.33)
Update: Skystar Bio-Pharmaceutical Company Q3 Earnings - Key Developments
David Zanoni - at Seeking Alpha - Wed Nov 19, 2:00AM CST
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Company (SKBI) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 17, 6:48PM CST
SKBI: 3.79 (-0.11)
Skystar Bio reports Q3 profit
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:20PM CST
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014.
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical to File Financial Results for Third Quarter of Fiscal 2014 on Friday, November 14
Marketwired - Fri Nov 14, 12:00PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the third quarter of fiscal 2014 on Friday, November 14, 2014 by close of the business day.
SKBI: 3.79 (-0.11)
Skystar Bio-Pharma Featured on Wide World of Stocks Television
Marketwired - Wed Nov 05, 1:33PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that the interview of Mr. Scott Cramer, Director, Corporate Development and U.S. Representative for Skystar, on Wide World of Stocks will broadcast today, Wednesday, November 5, 2014 into more than 50 million homes nationwide over BizTV, BizTV Radio, and You Tube America Networks.
SKBI: 3.79 (-0.11)
Market Maker Surveillance Report. BDR, HDY, LUNA, EFOI, SKBI, KUTV, Losing Stocks With Lowest Price Friction For Friday, September 12th 2014
M2 - Mon Sep 15, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4813 companies with "abnormal" market making, 1557 companies with positive Friction Factors and 3492 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Blonder Tongue Laboratories Inc (NYSE:BDR), Hyperdynamics Corp (NYSE:HDY), Luna Innovations Inc (NASDAQ:LUNA), Energy Focus Inc (NASDAQ:EFOI), Skystar Bio Pharmaceutical Co (NASDAQ:SKBI), Ku6 Media Co Ltd (NASDAQ:KUTV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SKBI: 3.79 (-0.11), LUNA: 1.38 (+0.02), EFOI: 5.18 (+0.14), BDR: 0.80 (+0.05), KUTV: 0.92 (unch), HDY: 0.67 (-0.04)
3 Stocks Under $10 Moving Higher
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
SKBI: 3.79 (-0.11), REPH: 10.71 (-0.78)
Skystar Bio-Pharmaceutical (SKBI) Upgraded From Hold to Buy
at The Street - Tue Sep 09, 8:21AM CDT
Skystar Bio-Pharmaceutical (SKBI) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
SKBI: 3.79 (-0.11)
Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014
Marketwire - Tue Aug 26, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced preparations to launch a new probiotic product for dairy cows by the end of fiscal 2014. The dairy cow probiotic is developed for the milk production industry in China and is designed to introduce Bacillus Subtilis (B. subtilis), also known as "Hay Bacillus," into the digestive tract of milk producing cows. Hay Bacillus has been proven to aid in the digestion and breakdown of hay in the animals' rumen canal.
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Reports Second Quarter Fiscal Year 2014 Financial Results
Marketwire - Thu Aug 14, 5:59PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2014 earnings, for the period ended June 30, 2014.
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday, August 14
Marketwire - Thu Aug 14, 5:31PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the second quarter of fiscal 2014 on Thursday, August 14, 2014 by close of the business day.
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Announces $5 Million Registered Direct Offering
Marketwire - Wed Jul 16, 7:59AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announces that it has entered into a definitive agreement with a dedicated healthcare institutional investor to purchase an aggregate of $5,000,000 of registered securities of the Company in a registered direct offering. Pursuant to the terms of the agreement, the investor shall purchase from the Company 790,514 shares of common stock and warrants to purchase up to 197,629 shares of common stock for an aggregate purchase price of $4,000,000 and 1,000 shares of convertible preferred stock and warrants to purchase up to 49,407 shares of common stock for an aggregate purchase price of $1,000,000.
SKBI: 3.79 (-0.11)
Skystar unveils new bovine IgG kits in China for domestic pig farming communities
M2 - Wed Jul 09, 6:32AM CDT
Veterinary company Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) reported on Tuesday the availability of its new product in China, called bovine immunoglobulin G (IgG) kits, targeting China's domestic pig farming communities.
SKBI: 3.79 (-0.11)
Skystar Launches Bovine Immunoglobulin G (IgG) Kits in China
Marketwire - Tue Jul 08, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announced the launch of a new product in China -- bovine immunoglobulin G (IgG) kits targeting China's domestic pig farming communities. This product helps to prevent and treat blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease which are common diseases affecting pig in the farming industry.
SKBI: 3.79 (-0.11)
23.3% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Mon Jul 07, 11:08AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 23.26% as of today's recent price of $7.79.
SKBI: 3.79 (-0.11)
12.7% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Fri Jun 27, 9:26AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 12.66% as of today's recent price of $7.12.
SKBI: 3.79 (-0.11)
InsiderInsights.com Daily Round Up 4/20/15: AXDX, BXMT, OPK, AGCO
InsiderInsights - at Seeking Alpha - Wed Apr 22, 10:38AM CDT
STFC: 23.83 (-0.01), SKBI: 3.79 (-0.11), DOOR: 68.54 (-0.82), MMI: 37.17 (-0.02), AGCO: 48.16 (-0.16), DEI: 29.37 (+0.22), ABDC: 13.70 (-0.19), CSX: 36.26 (+0.91), HOV: 3.36 (-0.08), MOH: 63.02 (-0.71), MEMP: 16.95 (-0.16), SFS: 18.08 (-0.49), AXDX: 23.62 (+0.10), OPK: 14.60 (+0.17), BXMT: 31.24 (+0.04), FELP: 13.99 (-0.33), CRM: 67.71 (+0.33)
Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K
Marketwired - Wed Apr 15, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market ("Nasdaq"
informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol. SKBI: 3.79 (-0.11)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 133.71 (+0.57), SKBI: 3.79 (-0.11), PTBI: 3.37 (+0.20), FMD: 6.56 (+0.01), GHC: 1,068.93 (+24.92), VRML: 1.80 (-0.02), ADBE: 75.50 (+0.88), OHAI: 5.59 (+0.03), KERX: 11.52 (-0.15), BH: 396.99 (-5.47), LII: 107.70 (+2.09), JAZZ: 186.13 (-0.41), NMBL: 24.61 (-0.13), REGN: 472.63 (+9.41), OAS: 16.47 (-0.36), XLRN: 33.67 (-0.02), SYK: 96.45 (+1.74), CRM: 67.71 (+0.33)
Update: Skystar Bio-Pharmaceutical Company Q3 Earnings - Key Developments
David Zanoni - at Seeking Alpha - Wed Nov 19, 2:00AM CST
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Company (SKBI) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 17, 6:48PM CST
SKBI: 3.79 (-0.11)
Skystar Bio reports Q3 profit
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:20PM CST
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"
, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014. SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical to File Financial Results for Third Quarter of Fiscal 2014 on Friday, November 14
Marketwired - Fri Nov 14, 12:00PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"
, a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the third quarter of fiscal 2014 on Friday, November 14, 2014 by close of the business day. SKBI: 3.79 (-0.11)
Skystar Bio-Pharma Featured on Wide World of Stocks Television
Marketwired - Wed Nov 05, 1:33PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that the interview of Mr. Scott Cramer, Director, Corporate Development and U.S. Representative for Skystar, on Wide World of Stocks will broadcast today, Wednesday, November 5, 2014 into more than 50 million homes nationwide over BizTV, BizTV Radio, and You Tube America Networks.
SKBI: 3.79 (-0.11)
Market Maker Surveillance Report. BDR, HDY, LUNA, EFOI, SKBI, KUTV, Losing Stocks With Lowest Price Friction For Friday, September 12th 2014
M2 - Mon Sep 15, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4813 companies with "abnormal" market making, 1557 companies with positive Friction Factors and 3492 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Blonder Tongue Laboratories Inc (NYSE:BDR), Hyperdynamics Corp (NYSE:HDY), Luna Innovations Inc (NASDAQ:LUNA), Energy Focus Inc (NASDAQ:EFOI), Skystar Bio Pharmaceutical Co (NASDAQ:SKBI), Ku6 Media Co Ltd (NASDAQ:KUTV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SKBI: 3.79 (-0.11), LUNA: 1.38 (+0.02), EFOI: 5.18 (+0.14), BDR: 0.80 (+0.05), KUTV: 0.92 (unch), HDY: 0.67 (-0.04)
3 Stocks Under $10 Moving Higher
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
SKBI: 3.79 (-0.11), REPH: 10.71 (-0.78)
Skystar Bio-Pharmaceutical (SKBI) Upgraded From Hold to Buy
at The Street - Tue Sep 09, 8:21AM CDT
Skystar Bio-Pharmaceutical (SKBI) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
SKBI: 3.79 (-0.11)
Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014
Marketwire - Tue Aug 26, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced preparations to launch a new probiotic product for dairy cows by the end of fiscal 2014. The dairy cow probiotic is developed for the milk production industry in China and is designed to introduce Bacillus Subtilis (B. subtilis), also known as "Hay Bacillus," into the digestive tract of milk producing cows. Hay Bacillus has been proven to aid in the digestion and breakdown of hay in the animals' rumen canal.
SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Reports Second Quarter Fiscal Year 2014 Financial Results
Marketwire - Thu Aug 14, 5:59PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"
, a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2014 earnings, for the period ended June 30, 2014. SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday, August 14
Marketwire - Thu Aug 14, 5:31PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"
, a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the second quarter of fiscal 2014 on Thursday, August 14, 2014 by close of the business day. SKBI: 3.79 (-0.11)
Skystar Bio-Pharmaceutical Announces $5 Million Registered Direct Offering
Marketwire - Wed Jul 16, 7:59AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announces that it has entered into a definitive agreement with a dedicated healthcare institutional investor to purchase an aggregate of $5,000,000 of registered securities of the Company in a registered direct offering. Pursuant to the terms of the agreement, the investor shall purchase from the Company 790,514 shares of common stock and warrants to purchase up to 197,629 shares of common stock for an aggregate purchase price of $4,000,000 and 1,000 shares of convertible preferred stock and warrants to purchase up to 49,407 shares of common stock for an aggregate purchase price of $1,000,000.
SKBI: 3.79 (-0.11)
Skystar unveils new bovine IgG kits in China for domestic pig farming communities
M2 - Wed Jul 09, 6:32AM CDT
Veterinary company Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) reported on Tuesday the availability of its new product in China, called bovine immunoglobulin G (IgG) kits, targeting China's domestic pig farming communities.
SKBI: 3.79 (-0.11)
Skystar Launches Bovine Immunoglobulin G (IgG) Kits in China
Marketwire - Tue Jul 08, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announced the launch of a new product in China -- bovine immunoglobulin G (IgG) kits targeting China's domestic pig farming communities. This product helps to prevent and treat blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease which are common diseases affecting pig in the farming industry.
SKBI: 3.79 (-0.11)
23.3% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Mon Jul 07, 11:08AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 23.26% as of today's recent price of $7.79.
SKBI: 3.79 (-0.11)
12.7% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Fri Jun 27, 9:26AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 12.66% as of today's recent price of $7.12.
SKBI: 3.79 (-0.11)
